{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:52:05Z","timestamp":1792759925718,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Atopic dermatitis (AD) prevalence in elderly patients is increasing. Clinically, elderly AD may present with atypical phenotypes, making the diagnosis difficult. Moreover, treatment challenges arise due to treatment-resistance, comorbidities, polypharmacy, and contraindications to existing therapies. Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) may offer a valuable alternative. However, their use in elderly populations remains unclear, as older patients are often excluded from clinical trials, and several concerns have been raised about their safety in this category of subjects. This study aimed to evaluate the efficacy and safety of JAK inhibitors in elderly patients with moderate-to-severe AD. A 52-week, multicenter, real-life study was performed enrolling patients aged\u2009\u2265\u200960\u00a0years affected by moderate-to-severe AD undergoing treatment with JAK inhibitors for at least 16\u00a0weeks across 16 dermatological centers in Italy. Disease severity was assessed at baseline, week (W) 4, 16, 24, and 52 using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and Pruritus-Numerical Rating Scale (P-NRS). Adverse events (AEs) were recorded at each follow-up. A total of 72 patients met the inclusion criteria [abrocitinib: 13 (18.06%); baricitinib: 6 (8.33%); upadacitinib: 53 (73.61%)]. Of these, 72 (100.0%) achieved W16 follow-up with 33 (45.83%) and 26 (36.11%) subjects reaching W24 and W52, respectively. At baseline, mean EASI, DLQI and P-NRS were 21.22\u2009\u00b1\u200910.38, 18.21\u2009\u00b1\u20097.33, and 7.84\u2009\u00b1\u20091.94, respectively. A significant improvement in all scores was observed starting from W4 [EASI: 4.77\u2009\u00b1\u20095.07, DLQI: 4.01\u2009\u00b1\u20093.98, P-NRS: 1.66\u2009\u00b1\u20091.83 (p\u2009&lt;\u20090.0001 for all)], continuing to improve up to W52 [EASI: 0.81\u2009\u00b1\u20091.27, DLQI: 0.31\u2009\u00b1\u20090.63, P-NRS: 0.42\u2009\u00b1\u20091.03; (p\u2009&lt;\u20090.0001 for all)]. No treatment interruptions or modifications for ineffectiveness or AEs were registered. No statistically significant differences in terms of efficacy and safety were found among the treatment groups. JAK inhibitors demonstrated significant efficacy and an acceptable safety profile in elderly AD patients.<\/jats:p>","DOI":"10.1007\/s00403-025-04278-9","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:10:09Z","timestamp":1748002209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of JAK inhibitors in patients aged &gt;\u200960 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study\u2014IL AD (Italian Landscape Atopic Dermatitis)"],"prefix":"10.1007","volume":"317","author":[{"given":"Luca","family":"Potestio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Sciarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Tirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo Raffaele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Savoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"4278_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40272-022-00499-x","volume":"24","author":"LF Eichenfield","year":"2022","unstructured":"Eichenfield LF, Stripling S, Fung S, Cha A, O\u2019Brien A, Schachner LA (2022) Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs 24:293\u2013305","journal-title":"Paediatr Drugs"},{"key":"4278_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/08923973.2021.1889583","volume":"43","author":"DS Mandlik","year":"2021","unstructured":"Mandlik DS, Mandlik SK (2021) Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol 43:105\u2013125","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"4278_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/ggi.12771","volume":"16","author":"R Tanei","year":"2016","unstructured":"Tanei R, Hasegawa Y (2016) Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int 16:75\u201386","journal-title":"Geriatr Gerontol Int"},{"key":"4278_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258219","volume":"16","author":"LN Chan","year":"2021","unstructured":"Chan LN, Magyari A, Ye M, Al-Alusi NA, Langan SM, Margolis D et al (2021) The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom. PLoS ONE 16:e0258219","journal-title":"PLoS ONE"},{"issue":"6","key":"4278_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/ijd.14891","volume":"59","author":"C Chello","year":"2020","unstructured":"Chello C, Carnicelli G, Sernicola A et al (2020) Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol 59(6):716\u2013721","journal-title":"Int J Dermatol"},{"key":"4278_CR6","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA et al (2017) Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 139:S58\u2013S64","journal-title":"J Allergy Clin Immunol"},{"key":"4278_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/ACI.0000000000000837","volume":"22","author":"C Patruno","year":"2022","unstructured":"Patruno C, Potestio L, Napolitano M (2022) Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol 22:242\u2013249","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4278_CR8","doi-asserted-by":"publisher","first-page":"adv13363","DOI":"10.2340\/actadv.v103.13363","volume":"103","author":"M Maurelli","year":"2023","unstructured":"Maurelli M, Chiricozzi A, Peris K, Gisondi P, Girolomoni G (2023) Atopic dermatitis in the elderly population. Acta Derm Venereol 103:adv13363","journal-title":"Acta Derm Venereol"},{"key":"4278_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S et al (2022) European guideline (EuroGuiDerm) on atopic eczema \u2013 part I: systemic therapy. J Eur Acad Dermatol Venereol 36:1409\u20131431","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4278_CR10","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1080\/09546634.2022.2102121","volume":"33","author":"C Patruno","year":"2022","unstructured":"Patruno C, Potestio L, Scalvenzi M et al (2022) Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat 33:3028\u20133033","journal-title":"J Dermatolog Treat"},{"key":"4278_CR11","first-page":"419","volume":"158","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Potestio L, Menna L, Megna M, Fabbrocini G, Patruno C (2023) Tralokinumab in elderly atopic dermatitis. Ital J Dermatol Venerol 158:419\u2013420","journal-title":"Ital J Dermatol Venerol"},{"key":"4278_CR12","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/DER.0000000000000686","volume":"32","author":"F Russo","year":"2021","unstructured":"Russo F, Milanesi N, Cartocci A et al (2021) Dupilumab in elderly patients with severe atopic dermatitis. Dermatitis 32:S24\u2013S27","journal-title":"Dermatitis"},{"key":"4278_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, Napolitano M, Argenziano G et al (2021) Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35:958\u2013964","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4278_CR14","doi-asserted-by":"publisher","first-page":"11380","DOI":"10.3390\/ijms241411380","volume":"24","author":"JG Gatmaitan","year":"2023","unstructured":"Gatmaitan JG, Lee JH (2023) Challenges and Future Trends in Atopic Dermatitis. Int J Mol Sci 24:11380","journal-title":"Int J Mol Sci"},{"key":"4278_CR15","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic. [accessed 13 Dec 2024]"},{"key":"4278_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jcm12010207","volume":"12","author":"C Philippoteaux","year":"2022","unstructured":"Philippoteaux C, Deprez V, Nottez A, Cailliau E, Houvenagel E, Deprez X et al (2022) Characteristics of patients treated with JAK inhibitors in rheumatoid arthritis before versus after VTE risk warnings. J Clin Med 12:207","journal-title":"J Clin Med"},{"key":"4278_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","volume":"18","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Cohen SB (2022) Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol 18:301\u2013304","journal-title":"Nat Rev Rheumatol"},{"key":"4278_CR18","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","volume":"156","author":"M Lam","year":"2020","unstructured":"Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P et al (2020) Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. JAMA Dermatol 156:1240\u20131245","journal-title":"JAMA Dermatol"},{"key":"4278_CR19","doi-asserted-by":"publisher","first-page":"2245510","DOI":"10.1080\/09546634.2023.2245510","volume":"34","author":"F Piscazzi","year":"2023","unstructured":"Piscazzi F, Gargiulo L, Ibba L, Valenti M, Facheris P, Costanzo A et al (2023) Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients. J Dermatolog Treat 34:2245510","journal-title":"J Dermatolog Treat"},{"key":"4278_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15728","volume":"35","author":"N Hong","year":"2022","unstructured":"Hong N, Park SY, Kook HD et al (2022) Baricitinib rapidly relieves eczema associated pruritus in elderly patients. Dermatol Ther 35:e15728","journal-title":"Dermatol Ther"},{"key":"4278_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1468-3083.2012.04612.x","volume":"27","author":"R Tanei","year":"2013","unstructured":"Tanei R, Hasegawa Y, Sawabe M (2013) Abundant immunoglobulin E-positive cells in skin lesions support an allergic etiology of atopic dermatitis in the elderly. J Eur Acad Dermatol Venereol 27:952\u2013960","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"4278_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N (2025) A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus-experienced patients. J Am Acad Dermatol 92(5):1049\u20131055","journal-title":"J Am Acad Dermatol"},{"key":"4278_CR23","doi-asserted-by":"publisher","first-page":"adv41504","DOI":"10.2340\/actadv.v105.41504","volume":"105","author":"AR Schlosser","year":"2025","unstructured":"Schlosser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D (2025) Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm Venereol 105:adv41504","journal-title":"Acta Derm Venereol"},{"key":"4278_CR24","doi-asserted-by":"publisher","first-page":"adv00872","DOI":"10.2340\/actadv.v103.5243","volume":"103","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Van der Gang LF, Zuithoff NPA et al (2023) Effectiveness of Upadacitinib in patients with atopic dermatitis including those with inadequate response to Dupilumab and\/or Baricitinib: results from the BioDay Registry. Acta Derm Venereol 103:adv00872","journal-title":"Acta Derm Venereol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04278-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:10:12Z","timestamp":1748002212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4278"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04278-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"777"}}